Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design
Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteristics.
Video content above is prompted by the following:
- Over the last five years, how has the emergence of immunotherapy in advanced NSCLC shifted the treatment paradigm in terms of the use of PD-1 inhibitors as first-line therapy?
- Prior to this study, what was known about the survival outcomes of patients receiving PD-1 inhibitors when used as monotherapy in the treatment of advanced NSCLC?
- How have treatment considerations changed regarding the characteristics of patients receiving PD-1 inhibitors since the initiation of this trial?
Study Finds Adherence to Annual Lung Cancer Screening Linked to Higher Detection Rates
March 18th 2025Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung cancer detection rates observed in those who followed through on these screenings.
Read More
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
March 7th 2025The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
Read More
Study Explores Immunotherapy vs. Chemoimmunotherapy Decisions For Advanced Non-Small Lung Cancer
March 5th 2025The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more recent diagnosis and prior glucocorticoid/steroid use.
Read More
